RE:Pelareorep on Cover of Dec 2023 Clinical Cancer Research MaThis work in multiple myeloma continues to prove pelareorep's effectiveness in the treatment of multiple cancers.
“The ability of multiple myeloma cells to escape the immune system is one factor underlying relapse that has gained increasing attention over the last several years,” Dr. Nawrocki said. “The current study showed that adding PELA, to the standard bortezomib-Dex regimen leads to immune reprogramming. This may contribute to the sensitivity we observed in patients who had previously relapsed from bortezemib-Dex and other proteasome inhibitor-based regimens. We view this as an important validation of our preclinical research in this area.”
The researchers have already begun a follow up clinical trial that adds pembroluzimab (KEYTRUDA) to the PELA, dexamethasone and bortezomib combination.